Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Clinical trials sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., explained in plain language.
Pharmaceutical company manufacturing and developing drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New clotting factor shows promise for hemophilia a bleeds
Disease control OngoingThis phase 3 trial tests a lab-made clotting factor VIII in 60 people with severe hemophilia A. The treatment is given on-demand for new bleeding episodes or before surgery. The goal is to see if it safely and effectively stops bleeding and supports surgical recovery.
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New antibody drug aims to cut COPD attacks in half
Disease control OngoingThis phase 2 trial tests TQC2938, a lab-made antibody, in 256 people with moderate to severe COPD. The goal is to see if the drug can reduce the number of serious flare-ups over 24 weeks compared to a placebo. Participants receive injections and are monitored for safety and side …
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC